DUBLIN--(BUSINESS WIRE)--The "Minimally Invasive Weight Loss (Bariatric) Devices Market" report has been added to ResearchAndMarkets.com's offering.
The minimally invasive weight loss devices market was valued at more than $137m in 2016 and is expected to grow at a double-digit rate over the next 5 years.
This analysis includes a discussion of medical devices, market forecasts, competitors, and opportunities in the global minimally invasive weight loss (bariatric) devices market.
This market focuses on 3 core segments:
1) laparoscopic adjustable gastric banding systems
2) intragastric balloons
3) implantable neuroregulators/gastric stimulators, as well as emerging technologies.
Report Highlights
- The most promising segment is intragastric balloon systems, an area exhibiting significant growth potential and innovation.
- The US accounted for more than 1/3 of the total market in 2016 and is expected to experience growth approaching a 15% CAGR, however, selected markets OUS will also expand due to rising global rates of obesity.
- The overall market will be driven by highly favorable demographics, low penetration, strong demand for safe and effective nonsurgical weight loss therapies (filling an underserved market between weight loss drugs and drastic bariatric surgery), and increased adoption of next-generation, implantable weight loss technologies
Key Topics Covered:
Executive Summary
i. Report overview
ii. Obesity overview and prevalence
iii. Minimally invasive weight loss devices market
a. Selected market drivers and limiters
b. Laparoscopic adjustable gastric banding devices segment
c. Intragastric balloon systems segment
d. Implantable neuroregulators/gastric stimulation systems segment
e. Technology trends
f. Market leaders
g. Competitive strategies
h. Emerging competition/startups
iv. Methodology
1. Overview of Obesity
1.1 Classification of overweight and obesity
1.2 Co-morbidities
1.2.1 Diabetes and obesity
1.3 Obesity prevalence
1.3.1 Worldwide prevalence
1.3.2 US prevalence
1.3.3 Obesity forecast for the US, Japan, and five major EU markets
1.3.4 Obese adults with diabetes forecast (the US and five major EU markets)
1.3.5 Obesity forecasts for Brazil and China
1.4 Causes
1.5 Bariatric surgery
1.5.1 Risks and benefits
1.5.2 Physicians recommend bariatric surgery over obesity drugs
1.5.3 Costs of obesity and bariatric surgery
1.5.4 Gastric bypass
1.5.5 Sleeve gastrectomy
1.6 Minimally invasive weight loss alternatives
1.6.1 Laparoscopic adjustable gastric banding
1.6.2 Non-surgical intragastric balloon systems
1.6.3 Implantable vagal blocking/gastric stimulation devices
1.6.4 Emerging minimally or non-invasive options
1.7 Bibliography
2. Laparoscopic Adjustable Gastric Banding Systems
2.1 Leading LAGB systems
2.1.1 Apollo Endosurgery
2.1.1.1 Additional clinical data
2.1.1.1.1 Band erosion and high failure rate
2.1.1.2 Cost and reimbursement
2.1.2 Ethicon/Johnson & Johnson
2.1.3 Other LAGB systems (available outside the US)
2.1.3.1 Agency for Medical Innovations
2.1.3.2 Cousin Biotech
2.1.3.3 Hlioscopie
2.1.3.4 Mdical Innovation Dveloppement
2.2 Bibliography
3. Intragastric Balloon Systems
3.1 Safety and efficacy
3.1.1 FDA warning
3.2 Allurion Technologies
3.3 Apollo Endosurgery
3.4 Hlioscopie
3.5 Obalon Therapeutics
3.6 ReShape Medical
3.7 Spatz FGIA
4. Implantable Vagal Blocking Therapy
4.1 EnteroMedics
4.1.1 Device components and mechanism of action
4.1.2 Clinical trial results
4.1.3 Reimbursement issues
4.2 MetaCure
5. Emerging Minimally Invasive Weight Loss Devices
5.1 Aspire Bariatrics
5.2 BarioSurg/EnteroMedics
5.3 BAROnova
5.4 GI Dynamics
5.5 GI Windows
5.6 Scientific Intake
6. Minimally Invasive Weight Loss Devices Market
6.1 Global market analysis
6.1.1 Market forecast 2016-21
6.1.2 Market forecast by region
6.1.3 Market forecast by product
6.1.4 Market forecast exhibits
6.1.5 Competitive analysis: laparoscopic adjustable gastric banding systems
6.1.6 Competitive analysis: intragastric balloon systems
6.1.7 Competitive analysis: implantable neuroregulators (vagal blocking) and gastric stimulation systems
6.1.8 Detailed analysis, by competitor
6.1.8.1 Apollo Endosurgery
6.1.8.2 EnteroMedics
6.1.8.3 Obalon Therapeutics
6.2 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/zzdjwl/minimally?w=4
